A graduate student at the University of Saskatchewan (USask) is investigating whether compounds derived from cannabis could help reduce seizures in people with temporal lobe epilepsy, according to a university news release.

Theodor Zaharia, who recently earned his Bachelor of Science with high honours and the University Medal at USask's Fall Convocation on Nov. 10, is now pursuing a master's degree in the College of Pharmacy and Nutrition. His research focuses on positive allosteric modulators (PAMs) of the type 1 cannabinoid receptor (CB1R) — the same receptor activated by THC, the psychoactive compound in cannabis.

According to statistics cited by Zaharia, about one in 26 people will develop epilepsy in their lifetime, and roughly one-third of those individuals do not respond to existing anti-seizure medications. That gap in treatment options is what drives his work.

"Having seen firsthand the prevalence of this condition and how it has affected some of my peers' quality of life, I am motivated to help make a difference," Zaharia said in the USask release.

CB1R plays a key role in regulating neuron activity. Zaharia explained that PAMs are compounds that "tune up" the receptor's activity enough to produce therapeutic benefits, but without causing the "high" or dependency effects typically associated with cannabis use.

"Our goals are to determine how these PAMs alter behaviour, are metabolized, and reduce seizure activity," he said. "In doing so, we aim to also characterize cannabinoid-related neuronal pathways that may be changed in temporal lobe epilepsy."

Zaharia is co-supervised by Dr. Robert Laprairie of the College of Pharmacy and Nutrition and Dr. Justin Botterill of the College of Medicine. Laprairie holds the GlaxoSmithKline-Saskatchewan Chair in Drug Discovery and Development and serves on the board of Epilepsy Canada. Botterill is a systems neuroscientist whose lab studies the neurobiological mechanisms of temporal lobe epilepsy. The two laboratories have a long-standing collaboration on testing new drugs for their anti-seizure potential.

"Wanting to properly address both the pharmacology and neuroscience aspects of this project, we sought Dr. Botterill as a co-supervisor for his expertise on epilepsy and its CB1R-related interactions," Zaharia said.

Zaharia's interest in cannabinoid research began during his undergraduate studies at USask. After a summer project with Laprairie on the pharmacodynamics of β-caryophyllene derivatives, he developed a strong interest in pharmacology. He took neuroanatomy and neuroscience electives in his fourth year, which deepened his focus.

"While cannabinoids play different roles in various areas throughout the body, we see their highest level of activity in the nervous system," he said.

For his master's work, Zaharia is learning electrophysiological techniques in Botterill's lab to apply them to his research. The project uses mouse models of temporal lobe epilepsy to study how PAMs affect behaviour, metabolism, and seizure activity.

Zaharia, born and raised in Saskatoon, said the biomedical sciences program at USask prepared him well for graduate research. He credited the diversity of subjects and the passion of his professors for creating a rich learning environment.

Looking ahead, Zaharia plans to enter an MD program — ideally at USask — and pursue a career that bridges preclinical research and clinical practice.

"Following my master's degree I aim to enter an MD program — ideally at USask — with my long-term career goal being to engage with both preclinical and clinical aspects of health care, working at benchtop and bedside," he said.